Tumor News and Research

RSS

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Genetic tests represent future of cancer care for women

Important progress is being made in women's health through the use of genetic tests, particularly those that help women detect and treat cancer.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

A new Mayo Clinic study has found that Gamma Knife™ stereotactic radiosurgery is a safe and effective option for selected children with arteriovenous malformations. This study was presented at the American Association of Neurological Surgeons Annual Meeting in Philadelphia last week.

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

CEVEC, Aragen Bioscience announce strategic license agreement

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

11 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Research may aid in developing new cancer therapies

Immortality and uncontrolled cell division are the fundamental differences between cancer cells and normal cells.

11 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

Tumor News and Research

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Researchers develop new technology to manage prostate cancer treatment

Genetic tests represent future of cancer care for women

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

Oncos Therapeutics completes € 4 million investment from HealthCap

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEVEC, Aragen Bioscience announce strategic license agreement

Exelixis first-quarter revenues increase to $42.2 million

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Research may aid in developing new cancer therapies

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

UC San Diego researchers discover potential new treatment for familial adenomatous polyposis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News